Background and Objective: Simvastatin, a cholesterol‐lowering drug, also stimulates oral bone growth when applied topically, without systemic side‐effects. However, the mechanisms involved in vivo are not known. We hypothesized that bone morphogenetic protein‐2, nitric oxide synthase, and cyclooxygenase‐2 are involved, based on prior in vitro evidence.
Material and Methods: A rat bilateral mandible model, where 0.5 mg of simvastatin in methylcellulose gel was placed on one side and gel alone on the other, was used to quantify nitric oxide, cyclooxygenase‐2 and bone morphogenetic protein‐2 (via tissue extraction, enzyme activity or immunoassay), and to analyze the bone formation rate (via undecalcified histomorphometry). Cyclooxygenase‐2 and nitric oxide synthase inhibitors (NS‐398 and L‐NAME, respectively) were administered intraperitoneally.
Results: Simvastatin was found to stimulate local bone morphogenetic protein‐2, nitric oxide and the regional bone formation rate (p < 0.05), whereas NS‐398 inhibited bone morphogenetic protein‐2 and reduced the bone formation rate (p < 0.05).
Conclusion: These data suggest an association between simvastatin‐induced bone morphogenetic protein‐2 and bone formation in the mandibular microenvironment, and the negative effect of cyclooxygenase‐2 inhibitors on bone growth.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.